Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer

MLA

Julie Vanderpoel, et al. “Total Cost of Testing for Genomic Alterations Associated with Next-Generation Sequencing versus Polymerase Chain Reaction Testing Strategies among Patients with Metastatic Non-Small Cell Lung Cancer.” Journal of Medical Economics, vol. 25, no. 1, Mar. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....50ffb5861a6604dac18501b8d5c634ec&authtype=sso&custid=ns315887.

APA

Julie Vanderpoel, Andrea L. Stevens, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, & Laura Morrison. (2022). Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. Journal of Medical Economics, 25(1).

Chicago

Julie Vanderpoel, Andrea L. Stevens, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, and Laura Morrison. 2022. “Total Cost of Testing for Genomic Alterations Associated with Next-Generation Sequencing versus Polymerase Chain Reaction Testing Strategies among Patients with Metastatic Non-Small Cell Lung Cancer.” Journal of Medical Economics 25 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....50ffb5861a6604dac18501b8d5c634ec&authtype=sso&custid=ns315887.